SARS-CoV-2 inactivation in laboratory animal tissues with 4% formaldehyde or 5% glutaraldehyde for transfer to biosafety level 1 laboratories.
- Resource Type
- Academic Journal
- Authors
- Pilchová V; University of Veterinary Medicine Hannover, Hannover, Germany.; Elmontaser Mergani A; University of Veterinary Medicine Hannover, Hannover, Germany.; Clever S; University of Veterinary Medicine Hannover, Hannover, Germany.; Ciurkiewicz M; University of Veterinary Medicine Hannover, Hannover, Germany.; Becker K; University of Veterinary Medicine Hannover, Hannover, Germany.; Gerhauser I; University of Veterinary Medicine Hannover, Hannover, Germany.; Baumgärtner W; University of Veterinary Medicine Hannover, Hannover, Germany.; Volz A; University of Veterinary Medicine Hannover, Hannover, Germany.; von Köckritz-Blickwede M; University of Veterinary Medicine Hannover, Hannover, Germany.; Schulz C; University of Veterinary Medicine Hannover, Hannover, Germany.
- Source
- Publisher: Sage Country of Publication: United States NLM ID: 0312020 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1544-2217 (Electronic) Linking ISSN: 03009858 NLM ISO Abbreviation: Vet Pathol Subsets: MEDLINE
- Subject
- Language
- English
The SARS-CoV-2 pandemic required the immediate need to transfer inactivated tissue from biosafety level (BSL)-3 to BSL-1 areas to enable downstream analytical methods. No validated SARS-CoV-2 inactivation protocols were available for either formaldehyde (FA)-fixed or glutaraldehyde (GA)-fixed tissues. Therefore, representative tissue from ferrets and hamsters was spiked with 2.2 × 10 6 tissue culture infectious dose 50% per ml (TCID 50 /ml) SARS-CoV-2 or were obtained from mice experimentally infected with SARS-CoV-2. SARS-CoV-2 inactivation was demonstrated with 4% FA or 5% GA at room temperature for 72 hours by a titer reduction of up to 10 3.8 TCID 50 /ml in different animal tissues with a maximum protein content of 100 µg/mg and a thickness of up to 10 mm for FA and 8 mm for GA. Our protocols can be easily adapted for validating the inactivation of other pathogens to allow for the transfer of biological samples from BSL-3 areas to BSL-1 laboratories.
Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.